131 related articles for article (PubMed ID: 6328968)
1. Phase II clinical evaluation of dihydroxyanthracenedione in patients with advanced lung cancer.
Valdivieso M; Umsawasdi T; Spitzer G; Chiuten DF; Booser DJ; Dhingra HM; Bodey GP
Am J Clin Oncol; 1984 Jun; 7(3):241-4. PubMed ID: 6328968
[TBL] [Abstract][Full Text] [Related]
2. Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with upper gastrointestinal tumors. A preliminary report.
Bedikian AY; Stroehlein J; Korinek J; Karlin D; Valdivieso M; Bodey GP
Am J Clin Oncol; 1983 Aug; 6(4):473-6. PubMed ID: 6869318
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanoma.
Arseneau JC; Schoenfeld DA; Borden EC
Invest New Drugs; 1986; 4(1):53-6. PubMed ID: 3700041
[TBL] [Abstract][Full Text] [Related]
4. An EORTC phase II study of mitoxantrone in solid tumors and lymphomas.
De Jager R; Cappelaere P; Armand JP; Keiling R; Fargeot P; Bastit P; van Glabbeke M; Renard J; Earl H; Rubens R
Eur J Cancer Clin Oncol; 1984 Nov; 20(11):1369-75. PubMed ID: 6542006
[TBL] [Abstract][Full Text] [Related]
5. Southwest Oncology Group study of Mitoxantrone for treatment of patients with advanced squamous cell carcinoma of the head and neck.
Mattox DE; Clark GM; Balcerzak SP; O'Bryan RM; Oishi N; Stuckey WJ
Invest New Drugs; 1984; 2(4):405-7. PubMed ID: 6511243
[TBL] [Abstract][Full Text] [Related]
6. Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with metastatic colorectal cancer.
Bedikian AY; Stroehlein J; Korinek J; Karlin D; Valdivieso M; Bodey GP
Am J Clin Oncol; 1983 Feb; 6(1):45-8. PubMed ID: 6837506
[TBL] [Abstract][Full Text] [Related]
7. Phase I clinical study of dihydroxyanthracenedione administered on a 5-day iv schedule.
Valdivieso M; Bedikian AY; Burgess MA; Savaraj N; Jeffers WB; Bodey GP
Cancer Treat Rep; 1981; 65(9-10):841-4. PubMed ID: 7273017
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of mitoxantrone in patients with non-small cell lung cancer.
Suga J; Saijo N; Shinkai T; Eguchi K; Sasaki Y; Sakurai M; Sano T; Tamura T; Hoshi A
Jpn J Clin Oncol; 1986 Jun; 16(2):147-51. PubMed ID: 3735704
[TBL] [Abstract][Full Text] [Related]
9. Mitoxantrone for treatment of patients with refractory small cell carcinoma of the lung: a Southwest Oncology Group Study.
Von Hoff DD; Chen T; Clark GM; Callahan SK; Livingston R
Cancer Treat Rep; 1983 Apr; 67(4):403-4. PubMed ID: 6303588
[No Abstract] [Full Text] [Related]
10. Phase II trial of mitoxantrone in previously untreated patients with colorectal adenocarcinoma: A Southwest Oncology Group Study.
Cowan JD; Von Hoff DD; McDonald B; Talley RW; McCracken JD; Chen T
Cancer Treat Rep; 1982 Sep; 66(9):1779-80. PubMed ID: 7116355
[No Abstract] [Full Text] [Related]
11. Mitoxantrone for the treatment of advanced breast cancer: single-agent therapy in previously untreated patients.
Cornbleet MA; Stuart-Harris RC; Smith IE; Coleman RE; Rubens RD; McDonald M; Mouridsen HT; Rainer H; van Oosterom AT; Smyth JF
Eur J Cancer Clin Oncol; 1984 Sep; 20(9):1141-6. PubMed ID: 6541135
[TBL] [Abstract][Full Text] [Related]
12. Phase II studies of mitoxantrone in patients with primary liver cancer.
Falkson G; Coetzer BJ
Invest New Drugs; 1985; 3(2):187-9. PubMed ID: 4019121
[TBL] [Abstract][Full Text] [Related]
13. Phase II study of mitoxantrone in advanced squamous cell carcinoma of the head and neck. A Southeastern Cancer Study Group trial.
Williams SD; Birch R; Velez-Garcia E; Gams R
Invest New Drugs; 1985; 3(3):311-3. PubMed ID: 4066226
[TBL] [Abstract][Full Text] [Related]
14. Phase II studies of mitoxantrone (dihydroxyanthracenedione) in the treatment of advanced colorectal carcinoma.
DeSimone PA; Gams R; Bartolucci A
Am J Clin Oncol; 1984 Oct; 7(5):517-22. PubMed ID: 6507372
[TBL] [Abstract][Full Text] [Related]
15. High-dose cisplatin with fluid and mannitol-induced diuresis in advanced lung cancer: a phase II clinical trial of the EORTC Lung Cancer Working Party (Belgium).
De Jager R; Longeval E; Klastersky J
Cancer Treat Rep; 1980; 64(12):1341-6. PubMed ID: 6258791
[TBL] [Abstract][Full Text] [Related]
16. Mitoxantrone as first-line chemotherapy in advanced breast cancer: results of a collaborative European study.
Mouridsen HT; Cornbleet M; Stuart-Harris R; Smith I; Coleman R; Rubens R; McDonald M; Rainer H; van Oosterom A; Smyth J
Invest New Drugs; 1985; 3(2):139-48. PubMed ID: 4019118
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone: a phase II study in the treatment of patients with advanced breast carcinoma and other solid tumours.
Stuart-Harris RC; Smith IE
Cancer Chemother Pharmacol; 1982; 8(2):179-82. PubMed ID: 7105382
[TBL] [Abstract][Full Text] [Related]
18. Mitoxantrone: an active new agent in the treatment of advanced breast cancer.
Stuart-Harris RC; Bozek T; Pavlidis NA; Smith IE
Cancer Chemother Pharmacol; 1984; 12(1):1-4. PubMed ID: 6690066
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy for advanced adenocarcinoma and squamous cell carcinoma of the lung with etoposide and cisplatin.
Dhingra HM; Valdivieso M; Booser DJ; Umsawasdi T; Carr DT; Chiuten DF; Murphy WK; Issell BF; Spitzer G; Farha P
Cancer Treat Rep; 1984 Apr; 68(4):671-3. PubMed ID: 6538811
[TBL] [Abstract][Full Text] [Related]
20. Phase II evaluation of mitoxantrone in advanced carcinoma of the stomach: a Southeastern Cancer Study Group Trial.
DeSimone PA; Gams R; Birch R
Cancer Treat Rep; 1986 Aug; 70(8):1043-4. PubMed ID: 3524836
[No Abstract] [Full Text] [Related]
[Next] [New Search]
